The next annual symposium of the European LeukemiaNet (ELN) is planned in Mannheim on September 7, 2021. Corona permitting, it will be organized as a physical event. ELN is a highly valued HARMONY partner.
Topics of the ELN symposium to be addressed are scientific updates in ALL, AML, CLL, CML, MDS, MPN, immunophenotyping, transplantation and Biometry. Many HARMONY KOLs and Research Project Leaders will present i.e. attend.
ELN is a publicly funded research network of excellence that aims to improve the treatment of leukemia through coordinated research efforts across Europe.
HARMONY Partner Rüdiger Hehlmann, Professor of Medicine and founder and chair of the European LeukemiaNet: "HARMONY is focusing on a broad range of blood cancers, including acute and chronic leukemias, and the ELN has has joined HARMONY from the start. By assembling anonymized data sets of thousands of patients into the unique HARMONY Big Data Platform, we can characterize the molecular landscape of these diseases, understand their pathophysiology, and identify novel drug targets. In addition, it will allow us to reliably predict disease course and drug response for subgroups of patients. HARMONY’s results should ultimately provide tools for healthcare professionals to rapidly select the most promising treatment for an individual patient with leukemia."
HARMONY Big Data Research Projects address specific questions for blood cancer research
We are looking forward to present at the upcoming ELN symposium. The key outstanding questions in the hematology field can only be answered by studying large numbers of patients. We developped the HARMONY Big Data Platform, assembling harmonized clinical data from over 70.000 of European patients. This will enable HARMONY researchers to characterize the molecular landscape of the various blood cancers (among which leukemias), understand their pathophysiology, and identify novel drug targets. In addition, it will allow to reliably predict disease course and drug response for subgroups of patients.
#BigDataforbloodcancer | Big Data accelerate better and faster treatment for Patients with Hematologic Malignancies
The HARMONY Alliance is a European Public–Private Partnership for Big Data in Hematology that is capturing and mining Big Data on various Hematologic Malignancies. The HARMONY Alliance, funded by Innovative Medicines Initiative, unites more than 100 organizations such as European medical associations, hospitals, research institutes, patient organizations, pharmaceutical and IT companies. HARMONY uses Big Data analytics to accelerate the development of more effective treatments for blood cancer patients. The aim is to accelerate the development of more effective treatments. Data are stored in HARMONY’s Big Data Platform, which has already identified over 70,000 anonymized patient records, making it one of the largest databases of its kind. Leading research teams are currently using this wealth of information to answer critical questions about hematologic malignancies that cannot be addressed with other methods.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
